Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels

By Reuters News

Oct 5 (Reuters) - BridgeBio Pharma, Inc. BBIO.O:

  • BBP-418 DEMONSTRATES POTENTIAL TO BE DISEASE MODIFYING THERAPY, RESTORING CARDIAC AND DISEASE MARKERS TO UNAFFECTED LEVELS

  • BRIDGEBIO PHARMA - 100% OF BBP-418-TREATED LGMD2I/R9 PATIENTS NORMALIZE HS TROPONIN I AT MONTH 12

  • BRIDGEBIO PHARMA - BBP-418 UNDER FDA PRIORITY REVIEW WITH PDUFA DATE NOVEMBER 27, 2026

  • BRIDGEBIO PHARMA - BBP-418 MET ALL PRIMARY AND SECONDARY ENDPOINTS AT 12-MONTH INTERIM PHASE 3 FORTIFY TRIAL

Further company coverage: BBIO.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.